GRAIL, Inc. (BMV:GRAL)
1,560.00
0.00 (0.00%)
At close: Oct 28, 2025
GRAIL Company Description
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAIL, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 1,000 |
| CEO | Robert Ragusa |
Contact Details
Address: 1525 O’Brien Drive Menlo Park, Delaware 94025 United States | |
| Phone | 833 694 2553 |
| Website | grail.com |
Stock Details
| Ticker Symbol | GRAL |
| Exchange | Mexican Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Robert Ragusa | Chief Executive Officer |
| Aaron Freidin | Chief Financial Officer |
| Paul Ciccolella | Chief Operating Officer |